ADIA Nutrition Unveils Adia Labs LLC: A New Era in Regenerative Medicine

ADIA Nutrition Inc. (OTC Pink: ADIA) has made a significant stride in the regenerative medicine sector with the launch of Adia Labs LLC, a new division dedicated to advancing stem cell therapies. This strategic move positions ADIA Nutrition at the forefront of the growing $15.1 billion global stem cell market, offering high-quality, FDA-compliant products to doctors and clinics nationwide.

Adia Labs LLC introduces two groundbreaking products, AdiaVita and AdiaLink, designed specifically for clinical research, studies, and trials. AdiaVita, a private-label product featuring umbilical cord stem cells, guarantees a minimum of 100 million viable cells and 3 trillion exosomes per unit. This product has undergone rigorous third-party verification to ensure unparalleled quality, purity, and potency. AdiaLink, coming soon, will offer exosomes with a guaranteed count of 3.5 trillion per unit, exclusively for use in clinical studies, trials, and research by doctors and clinics.

The establishment of Adia Labs was made possible through a groundbreaking deal with an esteemed FDA-approved laboratory. This partnership allows ADIA Nutrition to offer AdiaVita under its own brand, ensuring that the products meet the highest standards of efficacy and safety. This collaboration leverages the lab's expertise in stem cell technology, reinforcing ADIA Nutrition's mission to provide cutting-edge, quality-driven health solutions.

Larry Powalisz, CEO of ADIA Nutrition, stated, "Our expansion into regenerative medicine is more than just growth; it's a step towards redefining healthcare. With Adia Med and now Adia Labs, we are dedicated to advancing medical science while maintaining the highest standards of quality and safety. Through our research, we estimate that we have over one million doctors and/or clinics as our potential client base."

Adia Labs is set to meet the growing demand for non-invasive, biological treatments for various conditions, including autoimmune diseases, degenerative disorders, and recovery from injuries. With its unique composition, Adia Labs aims to offer an accessible and effective solution for those seeking the benefits of stem cell therapy.

Doctors and clinics nationwide can now purchase these umbilical cord stem cell and exosome products for research, trials, and studies from Adia Labs. For pricing and further information, they should visit adialabs.com.

With stem cells, Adia Med opens new avenues for repairing and regenerating damaged tissues, providing hope for various health conditions such as autoimmune or cognitive diseases. This launch not only expands ADIA Nutrition's product line but also positions them at the forefront of regenerative medicine, promoting a future where innovative treatments are more accessible and effective.

For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition



Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publish any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.